Targeted therapies in bone sarcomas: current approach and future directions

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
   PubMed Web of Science ®Google Scholar
• Hauben EI, Arends J, Vandenbroucke JP, Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Hum Genet 2003;11(8):611-18
   PubMed Web of Science ®Google Scholar
• Yu CL, Tucker MA, Abramson DH, Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 2009;101(8):581-91
   PubMed Web of Science ®Google Scholar
• Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop Relat Res 2002;(397):40-52
   PubMed Web of Science ®Google Scholar
• Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer 2009;115(7):1531-43
   PubMed Web of Science ®Google Scholar
• Huvos AG. Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. Cancer 1986;57(7):1442-9
   PubMed Web of Science ®Google Scholar
• Le Vu B, de Vathaire F, Shamsaldin A, Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer 1998;77(3):370-7
   PubMed Web of Science ®Google Scholar
• Nellissery MJ, Padalecki SS, Brkanac Z, Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am J Hum Genet 1998;63(3):817-24
   PubMed Web of Science ®Google Scholar
• Tang N, Song WX, Luo J, Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 2008;466(9):2114-30
   PubMed Web of Science ®Google Scholar
• Tsukita S, Yonemura S. ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr Opin Cell Biol 1997;9(1):70-5
   PubMed Web of Science ®Google Scholar
• Ferguson W, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001;19(3):23
   PubMedGoogle Scholar
• Stiller C, Bielack SS, Jundt G, Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System Project. Eur J Cancer 2006;42(13):11
   Google Scholar
• Miller R. Contrast epidemiology of childhood osteosarcoma, Ewing's tumor and rhabdomyosarcoma. Natl Cancer Inst Monogr 1981;(56):9-15
   PubMedGoogle Scholar
• de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000;18(1):204-13
   PubMed Web of Science ®Google Scholar
• Zucman J, Delattre O, Desmaze C, Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer 1992;5(4):271-7
   PubMed Web of Science ®Google Scholar
• Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24(16):7275-83
   PubMed Web of Science ®Google Scholar
• Cironi L, Riggi N, Provero P, IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One 2008;3(7):e2634
   PubMed Web of Science ®Google Scholar
• Tirado OM, Mateo-Lozano S, Villar J, Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res 2006;66(20):9937-47
   PubMed Web of Science ®Google Scholar
• Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res 2006;4(11):851-9
   PubMed Web of Science ®Google Scholar
• Smith R, Owen LA, Trem DJ, Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006;9(5):405-16
   PubMed Web of Science ®Google Scholar
• Luo W, Gangwal K, Sankar S, GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene 2009;28(46):4126-32
   PubMed Web of Science ®Google Scholar
• Takahashi A, Higashino F, Aoyogi M, EWS/ETS fusions activate telomerase in Ewing's tumor. Cancer Res 2003;63(23):6
   PubMedGoogle Scholar
• Schwab JH, Boland PJ, Agaram NP, Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunol Immunother 2009;58(3):339-49
   PubMed Web of Science ®Google Scholar
• Lagonigro MS, Tamborini E, Negri T, PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. J Pathol 2006;208(5):615-23
   PubMed Web of Science ®Google Scholar
• Grifone TJ, Haupt HM, Podolski V, Brooks JJ. Immunohistochemical expression of estrogen receptors in chondrosarcomas and enchondromas. Int J Surg Pathol 2008;16(1):31-7
   PubMed Web of Science ®Google Scholar
• Cleton-Jansen AM, van Beerendonk HM, Baelde HJ, Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res 2005;11(22):8028-35
   PubMed Web of Science ®Google Scholar
• Dohi O, Hatori M, Suzuki T, Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma. Cancer Sci 2008;99(3):518-23
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Hohenberger J, Bovee JV, Aromatase inhibition in patients with recurrent and/or metastatic chondrosarcoma. 2008 ASCO Annual Meeting Proceedings. J Clin Oncol 2008;26:10542
   Google Scholar
• Druker B. Imatinib (Gleevec) as a paradigm of targeted cancer therapies. Keio J Med 2010;59(1):1-3
   PubMedGoogle Scholar
• Grignani G, Palmerini E, Stacchiotti S, A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-alpha or -beta: an Italian Sarcoma Group study. Cancer 2011;117(4):826-31
   PubMed Web of Science ®Google Scholar
• Chao J, Budd GT, Chu P, Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res 2010;30(2):547-52
   PubMed Web of Science ®Google Scholar
• Klenke FM, Abdollahi A, Bertl E, Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer 2007;7:49
   PubMed Web of Science ®Google Scholar
• Schrage YM, Briaire-de Bruijn IH, de Miranda NF, Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 2009;69(15):6216-22
   PubMed Web of Science ®Google Scholar
• Guba M, von Breitenbuch P, Steinbauer M, Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8(2):128-35
   PubMed Web of Science ®Google Scholar
• Khanna C, Wan X, Bose S, The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10(2):182-6
   PubMed Web of Science ®Google Scholar
• Brown EJ, Schreiber SL. A signaling pathway to translational control. Cell 1996;86(4):517-20
   PubMed Web of Science ®Google Scholar
• Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005;65(6):2406-11
   PubMed Web of Science ®Google Scholar
• Chawla S, Tolcher AW, Staddon AP, Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcoma : update of phase II trial. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(18s):10076
   Google Scholar
• Kappel CC, Velez-Yanguas MC, Hirschfeld S, Helman LJ. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 1994;54(10):2803-7
   PubMed Web of Science ®Google Scholar
• Olmos D, Postel-Vinay S, Molife LR, Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010;11(2):129-35
   PubMed Web of Science ®Google Scholar
• Pappo A, Patel S, Crowley J, Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor in patients with recurrent or refractory Ewing's sarcoma family of tumors: results of a phase II SARC study. 2010 ASCO Annual Meeting Proceedings. J Clin Oncol 2010;25(15s):10000
   Google Scholar
• Huang F, Greer A, Hurlburt W, The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 2009;69(1):161-70
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Manara MC, Hattinger CM, Prognostic and therapeutic relevance of Her2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005;41(9):12
   PubMedGoogle Scholar
• Ueda TK, Kakunaga S, Oka Y, Tumor immunotherapy targeting WT1 (Wilms' tumor gene) peptide for bone and soft-tissue sarcomas: a preliminary report. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(18S):10042
   Google Scholar
• Anninga JK, van de Vijver MJ, Cleton-Jansen AM, Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcoma. Eur J Cancer 2004;40(7):2
   Google Scholar
• Guan H, Jia SF, Zhou Z, Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo. Clin Cancer Res 2005;1(11):11
   Google Scholar
• Ueda T, Kakunaga S, Oka Y, Tumor immunotherapy targeting WT1 (Wilms' tumor gene) peptide for bone and soft-tissue sarcomas: a preliminary report. Paper presented at: ASCO Annual Meeting Proceedings 2007
   Google Scholar
• Herbst RS, Eckhardt SG, Kurzrock R, Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010;28(17):2839-46
   PubMed Web of Science ®Google Scholar
• Chawla SP, Chua VS, Fernandez L, Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma. Mol Ther 2009;17(9):1651-7
   PubMed Web of Science ®Google Scholar
• Lau Y, Sabokbar A, Gibbons CL. Phenotypic and molecular studies of giant cell tumor of bone and soft tissue. Hum Pathol 2005;36(9):9
   Google Scholar
• Thomas DM, Chawla S, Skubitz A, Denosumab for the treatment of giant cell tumor (GCT) of bone: final results form a proof-of-concept phase II study. Paper presented at: 2009 ASCO Annual Metting 2009
   Google Scholar
• Pisters PW, Leung DH, Woodruff J, Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:10
   Google Scholar